For that purpose, we developed several novel RevTMs with different structures and characteristics, specific for two highly expressed TAAs on GBM cells: Disialoganglioside (GD2) and the epidermal growth factor receptor (EGFR) (28–34). Here, EGFR is linked to glioblastoma.